SCHEMBL29489783

SCHEMBL29489783

CC(C)(C)OC(=O)N1C=CCN1C(=O)OC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CTSK P43235 1/20 0.40
PREP P48147 1/20 0.37
USP2 O75604 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
BCHE P06276 1/20 0.36
CHRM2 P08172 1/20 0.35
CHRM1 P11229 1/20 0.35
CHRM3 P20309 1/20 0.35
EPHX1 P07099 1/20 0.33
NR1H2 P55055 1/20 0.33
HPGD P15428 1/20 0.32
DGAT1 O75907 1/20 0.31
GPR119 Q8TDV5 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
ESR2 Q92731 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6203338 0.82 CTSK (0.50) CTSKPREPUSP2SMN1; SMN2BCHE
SCHEMBL900813 0.76 USP2 (0.37) CTSKPREPUSP2SMN1; SMN2CHRM2
SCHEMBL6203340 0.76 CTSK (0.45) CTSKPREPUSP2SMN1; SMN2BCHE
SCHEMBL17047027 0.75 MAPK1 (0.39) SMN1; SMN2BCHE
SCHEMBL6023105 0.73 CTSK (0.50) CTSKPREPUSP2SMN1; SMN2CHRM2
SCHEMBL222920 0.70 PREP (0.53) CTSKPREPUSP2SMN1; SMN2EPHX1
SCHEMBL6023110 0.69 CTSK (0.43) CTSKPREPUSP2SMN1; SMN2CHRM2
SCHEMBL7909692 0.68 USP2 (0.42) PREPUSP2SMN1; SMN2NR1H2HPGD
SCHEMBL3603586 0.67 CTSK (0.72) CTSKPREPUSP2SMN1; SMN2CHRM2
SCHEMBL900812 0.67 CTSK (0.67) CTSKPREPUSP2SMN1; SMN2CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376477-A1 ANALGESIC DELTA OPIOID RECEPTOR BITOPIC LIGANDS UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2025-12-11 US disclosed
US-20230310435-A1 HOST DEFENSE PROTEIN (HDP) MIMETICS FOR PROPHYLAXIS AND/OR TREATMENT OF INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACT INNOVATION PHARMACEUTICALS INC. (US) 2023-10-05 US disclosed
US-11666571-B2 Host defense protein (HDP) mimetics for prophylaxis and/or treatment of inflammatory diseases of the gastrointestinal tract INNOVATION PHARMACEUTICALS INC. (US) 2023-06-06 US disclosed
EP-4168030-A1 NOVEL ANTIBACTERIAL HYDROGELS NewSouth Innovations Pty Limited (AU) 2023-04-26 EP disclosed
US-20220267268-A1 NEW TRICYCLIC 5-HT2 ANTAGONISTS ANAMAR AB (SE) 2022-08-25 US disclosed
US-20220096641-A1 PYRROLOBENZODIAZEPINE DIMER COMPOUND WITH IMPROVED SAFETY AND USE THEREOF LEGOCHEM BIOSCIENCES, INC. (KR) 2022-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376477-A1 ANALGESIC DELTA OPIOID RECEPTOR BITOPIC LIGANDS OPRD1, OPRK1, OPRM1 CTSK 2905/4885PREP 1281/4885USP2 2527/4885
US-11666571-B2 Host defense protein (HDP) mimetics for prophylaxis and/or treatment of inflammatory diseases of the gastrointestinal tract FABP2, HMGB1, MASP2 CTSK 1255/4885PREP 222/4885USP2 2083/4885
US-20220267268-A1 NEW TRICYCLIC 5-HT2 ANTAGONISTS HTR2B, HTR2C, TPH2 CTSK 4005/4885PREP 2717/4885USP2 1975/4885
US-20220096641-A1 PYRROLOBENZODIAZEPINE DIMER COMPOUND WITH IMPROVED SAFETY AND USE THEREOF BID, CDC42, BAD CTSK 3095/4885PREP 1475/4885USP2 4221/4885
US-20230310435-A1 HOST DEFENSE PROTEIN (HDP) MIMETICS FOR PROPHYLAXIS AND/OR TREATMENT OF INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACT FABP2, HMGB1, MASP2 CTSK 1255/4885PREP 222/4885USP2 2083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.